The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

Learn about cost and Beyfortus, financial and insurance assistance, ways to lower long-term costs, and more.

Sanofi said Beyfortus duration of protection was extended for six months in the EU. This year’s EU shipments are marked by an important change to the Beyfortus EU label, extending the duration ...

Sanofi (NASDAQ:SNY) will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure widespread availability ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which typically runs ...

Beyfortus, a long-acting RSV antibody treatment for infants, will launch in Korea next month, aiming to address rising hospitalization rates linked to the virus, especially among children under ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in ...

Beyfortus made $1.8 billion in sales last year, even though supplies were held back by now-resolved production constraints.

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV ...

In addition to Beyfortus, the monoclonal antibody shot for babies younger than 8 months, an RSV vaccine for pregnant people became available, as did an RSV vaccine for adults ages 60 and older ...

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.